Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

50.76 +4.37 (+9.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crispr Therapeutics Ag

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
It won't be able to be profitable without hitting its targets for both of these figures. 
Via The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
The Ultimate Biotech Stock to Buy With $50 Right Now
This company might be worth far more than many realize. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The aggressive growth icon kicked off the new trading week by buying some of her favorite stocks. 
Via The Motley Fool
Why We Buy Stocks
Is fear of missing out (FOMO) controlling your portfolio? 
Via The Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market. 
Via The Motley Fool
Why I Keep Buying These 14 Incredible Growth Stocks
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is CRISPR Therapeutics Stock a Buy?
The markets this biotech is looking to enter could be extremely lucrative. 
Via The Motley Fool
2 Biotech Stocks That Are Screaming Buys This Month
They won't remain southbound forever. 
Via The Motley Fool
This Healthcare Growth Stock Could Be a Steal of a Deal Right Now
CRISPR Therapeutics is trading around multiyear lows. 
Via The Motley Fool
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks. 
Via The Motley Fool
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
Bargain hunters should love these great stocks. 
Via The Motley Fool
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
There's a lot of growth on the way, and soon. 
Via The Motley Fool
1 Biotech Stock Down 62% to Buy and Hold
It's an excellent opportunity to buy shares of what could become a biotech giant on the dip. 
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
An investment in these players today could score a big win down the road. 
Via The Motley Fool
Looking for Stock Bargains With Room to Run? Try This.
Investing tips from Bill Mann, The Motley Fool's director of small-cap research. 
Via The Motley Fool
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
Is the potential upside for CRISPR Therapeutics too massive to ignore? 
Via The Motley Fool
3 Monster Biotech Stocks to Buy Before 2025
These companies are nearly in the sweet spot of risk versus reward in biotech. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
The companies are chasing major innovations. 
Via The Motley Fool
Got the Market Sell-Off Blues? Do These 3 Things Right Now
You aren't powerless in the face of what the market throws at you. 
Via The Motley Fool
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is." 
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
CRSP Stock Earnings: CRISPR Therapeutics Beats EPS, Misses Revenue for Q2 2024
CRSP stock results show that CRISPR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Great companies are found in every type of market landscape. 
Via The Motley Fool
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
The biotech recently became a commercial-stage company. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.